NRx Pharmaceuticals, Inc. (NRXP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1201 Orange Street
Wilmington, DE 19801
United States of America (the)
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
December 04, 2017
| Name | Title | Pay | Year Born |
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | 846,774 | 1957 |
| Dennis K. McBride | Chief Strategy Officer & Director | 38,462 | 1955 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240,000 | 1962 |
| Michael S. Abrams | CFO & Treasurer | 363,083 | 1970 |
| Hervé Perron | Chief Scientist | 0 | 1959 |
| Philip T. Lavin | Chief Methodologist | 0 | 1947 |
| Glenn Tyson | Chief Commercial Officer | 0 | N/A |
| Joseph Casper | Chief Operating Officer | 0 | 1951 |
| Joshua C. Brown | Chief Medical Innovation Officer | 0 | N/A |
| Suzanne Messere | Investor Relations | 0 | N/A |
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.